Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer

Figure 1 Progression-free survival according to the CHAARTED and STAMPEDE definitions of progressive disease and Swedish national guidelines. Time from date of diagnosis to last follow-up/death. Censored at 36 mo. A: CHAARTED and STAMPEDE; B: Swedish national guidelines.

Figure 2 Progression-free survival for subgroups defined by PSA over/under median. A: Progression-free survival (PFS) according to the CHAARTED and STAMPEDE definitions of progressive disease (log-rank: P = 0.0027); B: PFS according to the Swedish national guidelines (log-rank: P = 0.0018). Time from date of diagnosis to last follow-up/death. Censored at 36 mo.